ClinicalTrials.gg
CompletedNCT01211873SENTIOUpdated Apr 18, 2019Results posted

Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions

A Phase 3 interventional study of Dotarem (gadoterate meglumine) and Magnevist (gadopentetate dimeglumine) in Diagnostic Self Evaluation and Central Nervous System Diseases, sponsored by Guerbet. Completed at 52 sites in 11 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2019-04-18.

Sponsored by Guerbet · Phase 3, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
416
Allocation
Randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 193 studies in Central Nervous System Diseases with a site in United States — 40 open to participants now, 49 under way, 4 of them phase 3. Central Nervous System Diseases · United States.

Enrollment
15th of 164
416 · median 50
Started
2010
with 8 others
Phase 3
25 of 193
none open now
Registered
38th of 193
by date

Among the 193 studies in Central Nervous System Diseases with a site in United States, this one is the 15th largest by enrollment of the 164 interventional ones that give a count, is one of 9 that started in 2010, is one of 25 in phase 3, and was the 38th registered.

Central Nervous System Diseases

386 studies on the registry are indexed under Central Nervous System Diseases; 104 are open to participants now.

Browse Central Nervous System Diseases studies →

Open to participants now

40 of the 193 studies in Central Nervous System Diseases with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Central Nervous System Diseases studies recruiting now, 34 (45%) set no upper age limit and 21 (28%) stop at 75 or younger; 10 take children under 18; 12 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 193 studies in Central Nervous System Diseases with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to look at the safety (what are the side effects)and efficacy (how well does it work) of Dotarem® when used in taking images of the brain / spine. The results will be compared to the results of MRI taken without Dotarem.

Read the detailed description

This is a study involving the use of Magnetic Resonance Imaging (MRI) contrast agents called Dotarem®. The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of Dotarem® when used for taking images of the brain and spine. The results of the MRI will be compared to the results of images taken without Dotarem®.

03

Conditions studied

  • Diagnostic Self Evaluation
  • Central Nervous System Diseases

Keywords

  • CNS
  • Contrast Agent
  • MRI
  • Dotarem
  • Magnevist
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult subject and pediatric subjects (aged greater than or equal to two (2) years).
  • Is referred for a contrast-enhanced MRI of the CNS based on the results of a previous imaging procedure.
  • Female of patients must have effective (contraceptive pill or intra-uterine device) or be surgically sterilized or (minimum 12 months amenorrhea), or have a documented negative urine pregnancy test within 24 hours prior to study MRI.
  • Has been fully informed about the study, and has consented to participate.

Exclusion criteria

Exclusion Criteria:

  • Having acute or chronic grade IV or V renal insufficiency.
  • Known class III/IV congestive heart failure.
  • Suffering from long syndrome.
  • Unstable health condition or circumstances (e.g. suffering from severe claustrophobia).
  • Having any to MRI such as a pace-maker, magnetic material or any other conditions that would preclude proximity to a strong magnetic field.
  • Known allergy to Gadolinium chelates.
  • Having received any contrast agent within 3 days prior to study contrast administration, or is scheduled to receive any contrast agent within 24 hours after the study contrast administration.
  • Pregnant, breast feeding, or planning to become pregnant during the trial.
  • Previously participated in this trial.
  • Having participated within 30 days in another clinical trial involving an drug.
  • Any condition which, based on the investigator's clinical judgement, would prevent the patient from completing all trial assessments and visits.
  • Inability or unwillingness to cooperate with the requirements of this trial.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
416 participants (actual)

Study arms

  • Experimental
    Dotarem (gadoterate meglumine )

    Dotarem and Magnevist were randomised as 2:1 ratio for adult patients.

    Drug: Dotarem (gadoterate meglumine)

  • Active comparator
    Magnevist (gadopentetate dimeglumine)

    Dotarem and Magnevist were randomised as 2:1 ratio

    Drug: Magnevist (gadopentetate dimeglumine)

  • Experimental
    Dotarem 2 (gadoterate meglumine )

    Pediatric patients were assigned to Dotarem group only.

    Drug: Dotarem (gadoterate meglumine)

Interventions

  • 0.1 mmol/kg by body weight, single IV injection

    Also known as: Dotarem

  • DrugMagnevist (gadopentetate dimeglumine)

    0.1 mmol/kg by body weight, single IV injection

    Also known as: Magnevist

06

What researchers measure

Primary outcomes

  1. MRI Lesion Visualization (Border Delineation, Internal Morphology and Contrast Enhancement) at Patient Level for Both "Pre" and "Paired" Evaluation

    To demonstrate the superiority of combined unenhanced and Dotarem enhanced MRI (PAIRED) compared to unenhanced MRI (PRE) in terms of lesion visualization. Unenhanced MRI refers to MRI before administration of contrast agent. Enhanced MRI refers to MRI after contrast agent injection. "Pre" refers to unenhanced MRI. "PAIRED" refer to combined unenhanced and enhanced MRI. The measure used a specific scale with 3-point levels to assess lesion visualization. At lesion level, the scale range is from 0 through 1 to 2. Score 0 means a worse outcome and score 2 means a better outcome. Patient score is the sum of all lesion scores. Up to 5 of the largest representative lesions were assessed. At patient level, the maximum score is 10, minimum score is 0.

    Time frame: up to 24 hours

Secondary outcomes

  1. Image Quality Score

    Image quality was evaluated for each lesion according to a 3-point scale with the following grades; poor (1), fair (2) or good (3), and an overall score per patient was calculated. At patient level, the maximum score is 3, minimum score is 1. Higher scores mean a better image quality.

    Time frame: up to 24 hours

  2. Diagnostic Confidence Score

    Level of diagnostic confidence when evaluating the MRI modalities was graded using a 5-point scale as nil (1), poor (2), moderate (3), high (4) and excellent (5).

    Time frame: up to 24 hours

  3. Number of Lesions

    The number of lesions for which observations could be made was calculated for each MRI modality and results are summarized per patient

    Time frame: up to 24 hours

07

Results

Posted May 29, 2014

Participant flow

First patient First Visit : 16 Sept 2010 Last patient Last Visit : 16 Nov 2011 Locations: radiology departments

Participant flow — Overall Study
MilestoneDotarem (Gadoterate Meglumine)Magnevist (Gadopentetate Dimeglumine)Dotarem 2 (Gadoterate Meglumine)
Started24511938
Completed24011736
Not completed522

Outcome measures

PrimaryMRI Lesion Visualization (Border Delineation, Internal Morphology and Contrast Enhancement) at Patient Level for Both "Pre" and "Paired" Evaluation

To demonstrate the superiority of combined unenhanced and Dotarem enhanced MRI (PAIRED) compared to unenhanced MRI (PRE) in terms of lesion visualization. Unenhanced MRI refers to MRI before administration of contrast agent. Enhanced MRI refers to MRI after contrast agent injection. "Pre" refers to unenhanced MRI. "PAIRED" refer to combined unenhanced and enhanced MRI. The measure used a specific scale with 3-point levels to assess lesion visualization. At lesion level, the scale range is from 0 through 1 to 2. Score 0 means a worse outcome and score 2 means a better outcome. Patient score is the sum of all lesion scores. Up to 5 of the largest representative lesions were assessed. At patient level, the maximum score is 10, minimum score is 0.

Time frame:
up to 24 hours
Reported as:
Mean · units on a scale
MRI Lesion Visualization (Border Delineation, Internal Morphology and Contrast Enhancement) at Patient Level for Both "Pre" and "Paired" Evaluation
units on a scaleDotarem (Gadoterate Meglumine) - PREDotarem (Gadoterate Meglumine) - PAIRED
Border Delineation Blinded Reader 11.06 ± 1.233.30 ± 2.64
Border Delineation Blinded Reader 21.62 ± 1.434.49 ± 2.94
Border Delineation Blinded Reader 31.43 ± 1.292.54 ± 2.30
Internal Morphology Blinded Reader 10.97 ± 1.053.70 ± 2.63
Internal Morphology Blinded Reader 21.76 ± 1.244.49 ± 2.93
Internal Morphology Blinded Reader 31.45 ± 1.132.93 ± 2.30
Contrast Enhancement Blinded Reader 10.01 ± 0.203.11 ± 2.52
Contrast Enhancement Blinded Reader 20.01 ± 0.153.73 ± 2.67
Contrast Enhancement Blinded Reader 30.01 ± 0.132.95 ± 2.44
Statistical analysis
  • Dotarem (Gadoterate Meglumine) - PRE vs Dotarem (Gadoterate Meglumine) - PAIRED · Regression, Logistic · p = <0.001
SecondaryImage Quality Score

Image quality was evaluated for each lesion according to a 3-point scale with the following grades; poor (1), fair (2) or good (3), and an overall score per patient was calculated. At patient level, the maximum score is 3, minimum score is 1. Higher scores mean a better image quality.

Time frame:
up to 24 hours
Reported as:
Mean · units on a scale
Image Quality Score
units on a scaleDotarem (Gadoterate Meglumine) - PREDotarem (Gadoterate Meglumine) - PAIREDMagnevist (Gadopentetate Dimeglumine) - PREMagnevist (Gadopentetate Dimeglumine) - PAIRED
Reader 11.41 ± 0.522.98 ± 0.201.42 ± 0.532.96 ± 0.26
Reader 21.72 ± 0.453.00 ± 01.74 ± 0.442.98 ± 0.19
Reader 32.00 ± 0.072.99 ± 0.111.99 ± 0.092.99 ± 0.09
Statistical analysis
  • Dotarem (Gadoterate Meglumine) - PRE vs Dotarem (Gadoterate Meglumine) - PAIRED · Regression, Logistic · p = <0.001
  • Magnevist (Gadopentetate Dimeglumine) - PRE vs Magnevist (Gadopentetate Dimeglumine) - PAIRED · Regression, Logistic · p = <0.001
SecondaryDiagnostic Confidence Score

Level of diagnostic confidence when evaluating the MRI modalities was graded using a 5-point scale as nil (1), poor (2), moderate (3), high (4) and excellent (5).

Time frame:
up to 24 hours
Reported as:
Mean · units on a scale
Diagnostic Confidence Score
units on a scaleDotarem (Gadoterate Meglumine) - PREDotarem (Gadoterate Meglumine) - PAIREDMagnevist (Gadopentetate Dimeglumine) - PREMagnevist (Gadopentetate Dimeglumine) - PAIRED
Reader 13.04 ± 0.904.59 ± 0.643.11 ± 0.864.66 ± 0.64
Reader 22.84 ± 0.614.89 ± 0.312.85 ± 0.594.92 ± 0.36
Reader 33.47 ± 1.224.41 ± 0.983.59 ± 1.294.59 ± 0.81
Statistical analysis
  • Dotarem (Gadoterate Meglumine) - PRE vs Dotarem (Gadoterate Meglumine) - PAIRED · Regression, Logistic · p = <0.001
  • Magnevist (Gadopentetate Dimeglumine) - PRE vs Magnevist (Gadopentetate Dimeglumine) - PAIRED · Regression, Logistic · p = <0.001
SecondaryNumber of Lesions

The number of lesions for which observations could be made was calculated for each MRI modality and results are summarized per patient

Time frame:
up to 24 hours
Reported as:
Mean · Number of lesions
Number of Lesions
Number of lesionsDotarem (Gadoterate Meglumine) - PREDotarem (Gadoterate Meglumine) - PAIREDMagnevist (Gadopentetate Dimeglumine) - PREMagnevist (Gadopentetate Dimeglumine) - PAIRED
Reader 11.97 ± 3.162.69 ± 4.711.98 ± 3.854.19 ± 10.54
Reader 22.29 ± 3.693.16 ± 5.212.60 ± 5.424.50 ± 9.95
Reader 31.97 ± 2.992.46 ± 4.532.15 ± 3.973.97 ± 10.02

Adverse events

Collected over Adverse events were collected from patient consent signature to the end of the last visits, maximum duration is 29 days.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dotarem (Gadoterate Meglumine )0/240 (0%)0/240 (0%)12/240 (5%)
Magnevist (Gadopentetate Dimeglumine)0/117 (0%)1/117 (0.9%)9/117 (7.7%)
Dotarem 2 (Gadoterate Meglumine )0/38 (0%)1/38 (2.6%)8/38 (21.1%)
Most frequent serious events
Most frequent serious events
EventDotarem (Gadoterate Meglumine )Magnevist (Gadopentetate Dimeglumine)Dotarem 2 (Gadoterate Meglumine )
hypoxiaRespiratory, thoracic and mediastinal disorders0/2400/1171/38
neurological decompensationNervous system disorders0/2400/1171/38
small intestine perforationGastrointestinal disorders0/2401/1170/38
Most frequent other events
Showing 10 of 13
Most frequent other events
EventDotarem (Gadoterate Meglumine )Magnevist (Gadopentetate Dimeglumine)Dotarem 2 (Gadoterate Meglumine )
headacheNervous system disorders1/2401/1172/38
blood urine presentInvestigations2/2400/1171/38
nauseaGastrointestinal disorders3/2400/1171/38
dizzinessNervous system disorders1/2400/1171/38
vomitingGastrointestinal disorders1/2400/1171/38
astheniaGeneral disorders0/2400/1171/38
application site erythemaGeneral disorders0/2400/1171/38
hypoxiaRespiratory, thoracic and mediastinal disorders0/2400/1171/38
pruritusSkin and subcutaneous tissue disorders0/2400/1171/38
injection site hematomaGeneral disorders0/2403/1170/38

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Magnevist (Gadopentetate Dimeglumine)Dotarem (Gadoterate Meglumine)Dotarem 2 (Gadoterate Meglumine)Total
<=18 years003838
Between 18 and 65 years891850274
>=65 years3060090
Age, Continuous
Age, Continuous(years)Magnevist (Gadopentetate Dimeglumine)Dotarem (Gadoterate Meglumine)Dotarem 2 (Gadoterate Meglumine)Total
Mean55.95 ± 14.4353.17 ± 14.359.29 ± 4.4949.8 ± 19.0
Sex: Female, Male
Sex: Female, Male(Participants)Magnevist (Gadopentetate Dimeglumine)Dotarem (Gadoterate Meglumine)Dotarem 2 (Gadoterate Meglumine)Total
Female6513122218
Male5411416184
Region of Enrollment
Region of Enrollment(participants)Magnevist (Gadopentetate Dimeglumine)Dotarem (Gadoterate Meglumine)Dotarem 2 (Gadoterate Meglumine)Total
United States306517112
France1330043
Argentina12221448
Brazil58417
Spain28010
Austria1020030
Chile35311
Germany2040060
United Kingdom3609
Italy715022
Korea, Republic of1426040
08

Study locations

52 sites
  • University of Alabama at Birmingham, UABMC
    Birmingham, Alabama 35233, United States
  • University Medical Center
    Tucson, Arizona 47404, United States
  • University medical center
    Tucson, Arizona 85724, United States
  • Desert Medical Imaging
    Indian Wells, California 47404, United States
  • Sunrise Clinical Research, Inc.
    Hollywood, Florida 33021, United States
  • Children's Memorial Hospital
    Chicago, Illinois 60614, United States
  • Precise Clinical Research Solutions
    Topeka, Kansas 66604, United States
  • University of Louisville Hospital
    Louisville, Kentucky 40202, United States
  • Neurocare Center for Research
    Brookline, Massachusetts 02446, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • QUEST Research Institute
    Farmington Hills, Michigan 48334, United States
  • Gruss Magnetic resonance Research Clinic
    New York, New York 10461, United States
  • WestImage - Division of Research
    Cincinnati, Ohio 45248, United States
  • Ohio State University
    Columbus, Ohio 47404, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • University of Texas - Health Science Center
    San Antonio, Texas 47404, United States
  • UTHSCSA
    San Antonio, Texas 47404, United States
  • Clinical Trials of Texas, Inc.
    San Antonio, Texas 78229, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
  • University of Wisconsin Hospital and Clinics
    Madison, Wisconsin 53792, United States
  • Centro de Diagnóstico
    Buenos Aires, Argentina
  • Hospital Italiano
    Buenos Aires, Argentina
  • TCBA
    Buenos Aires, Argentina
  • Univ.-institut f.Radiodiagnostik
    Salzburg, Austria
  • Landesklinikum Tulln
    Tulln, Austria
  • Medical University of Vienna
    Vienna, Austria
  • Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo
    São Paulo, Brazil
  • Universidade Federal de São Paulo / UNIFESP
    São Paulo, Brazil
  • Departamento de Neuroradiologia
    Santiago, Chile
  • Instituto de Neurocirugia Dr. Asenjo,
    Santiago, Chile
  • Hôpital Pellegrin
    Bordeaux, France
  • Hôpital Roger Salengro- CRHU de Lille
    Lille, France
  • Hôpital Gui De Chauliac
    Montpellier, France
  • Centre Hospitalier Sainte Anne
    Paris, France
  • Radiologie A - Hôpital de la Milétrie
    Poitiers, France
  • Fédération d'Imagerie Médicale,Hôpital Pontchaillou
    Rennes, France
  • University Hospital Charite
    Berlin, Germany
  • University Hospital Frankfurt
    Frankfurt/Main, Germany
  • Krankenhaus Nordwest GmbH
    Frankfurt, Germany
  • University of Heidelberg
    Heidelberg, Germany
  • University of Leipzig
    Leipzig, Germany
  • University Hospital Mannheim
    Mannheim, Germany
  • University Hospital LMU Munich
    Munich, Germany
  • Istituto di Radiologia
    Firenze, Italy
  • Neuroradiologia,II Università Di Napoli
    Napoli, Italy
  • Azienda Ospedaliera S. Andrea
    Roma, Italy
  • Samsung Medical Center
    Seoul, Korea, Republic of
  • Seoul National Unversity Hospital
    Seoul, Korea, Republic of
  • Hospital Vall d´Hebron
    Barcelona, Spain
  • Hospital Clinico Universitario San Carlos
    Madrid, Spain
  • Complejo Hospitalario Universitario de Vigo - Serviço de radiologia
    Vigo, Spain
  • University Department of Radiology
    Cambridge, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.

Results were first posted in May 2014, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2010
First posted
Sep 30, 2010
Start
Sep 2010
Primary completionActual
Nov 2011
CompletionActual
Nov 2011
Results first posted
May 29, 2014
Last update
Apr 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01211873
Lead sponsor
Guerbet
Responsible party
Sponsor
First posted
Sep 30, 2010
Start date
Sep 2010
Primary completion
Nov 2011
Completion
Nov 2011
Results posted
May 29, 2014
Last update
Apr 18, 2019

Study contacts

Ken Maravilla, MD
principal investigator · University of Wasington School of Medicine

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gadoterate meglumine

Start the discussion